WEDNESDAY, June 18, 2025 — Drugmaker

2025年6月18日，星期三——制药商

Eli Lilly

礼来公司

plans to buy

计划购买

Verve Therapeutics

Verve Therapeutics

, a gene-editing startup, for about $1 billion upfront.

，一家基因编辑初创公司，约 10 亿美元的预付款。

The deal gives Lilly a potential new treatment for heart disease,

该交易使礼来公司获得了一种潜在的心脏病新疗法，

The Wall Street Journal

《华尔街日报》

reported.

已报告。

The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as much as $300 million more if Verve’s top drug hits certain research milestones. That would bring the total deal $1.3 billion,

该交易于 6 月 17 日宣布，包括以每股 10.50 美元的价格收购所有已发行的 Verve 股票。如果 Verve 的主打药物达到某些研发里程碑，Lilly 还可能额外支付多达 3 亿美元。这将使交易总额达到 13 亿美元。

The WSJ

《华尔街日报》

reported.

已报告。

Verve’s board has agreed to the sale and recommends shareholders support the decisoin. The deal is expected to close by the third quarter of this year.

Verve的董事会已同意出售，并建议股东支持该决定。预计该交易将在今年第三季度前完成。

Verve is developing a new class of gene-editing drugs that could be given just once to treat chronic conditions. Its top drug — Verve-102 — is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

Verve正在开发一类新的基因编辑药物，这类药物只需一次治疗就可以应对慢性疾病。其主打药物——Verve-102——旨在靶向一种名为PCSK9的基因，该基因与心脏健康和胆固醇水平有关。

The treatment is being tested in a Phase 1b clinical trial and has received fast-track designation from the U.S. Food and Drug Administration (FDA),

该治疗正在 1b 期临床试验中进行测试，并已获得美国食品和药物管理局 (FDA) 的快速通道指定，

The WSJ

《华尔街日报》

added.

已添加。

“Verve-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,”

“Verve-102有潜力成为首个针对广泛患者群体的体内基因编辑疗法，并可能将心血管疾病的治疗模式从慢性护理转变为一次性治疗。”

Ruth Gimeno

鲁斯·希梅诺

, Lilly’s vice president of metabolic and diabetes drug development, said.

，礼来公司代谢和糖尿病药物开发副总裁说。

If the drug passes early trials and moves into a Phase 3 trial, Verve shareholders will receive an additional $3 per share. That payout would happen if the first patient receives the treatment within 10 years of the deal closing.

如果该药物通过早期试验并进入第 3 阶段试验，Verve 的股东将获得每股额外 3 美元的收益。如果在协议达成后的 10 年内第一名患者接受治疗，就会发生这笔付款。

Verve’s co-founder and CEO,

Verve的联合创始人兼首席执行官，

Dr. Sekar Kathiresan

Sekar Kathiresan 博士

, said the company was created with a bold goal: to change how heart disease is treated.

公司表示，该公司成立时设定了一个大胆的目标：改变心脏病的治疗方式。

“In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic,” he told

“在短短七年时间里，我们的团队已经研发出了三种体内基因编辑产品，其中两种目前正在临床试验中，”他说道

The WSJ

《华尔街日报》

. “Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly.”

“现在，我们将与理想的策略伙伴礼来公司一起，在药物开发的旅程中迈出下一步。”

Whatever your topic of interest,

无论你感兴趣的话题是什么，

subscribe to our newsletters

订阅我们的新闻通讯

to get the best of Drugs.com in your inbox.

获取 Drugs.com 的最新资讯到您的收件箱。